{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:16:18Z","timestamp":1790043378042,"version":"4.0.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T00:00:00Z","timestamp":1541808000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/ckj\/sfy100","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T15:20:41Z","timestamp":1536333641000},"page":"81-88","source":"Crossref","is-referenced-by-count":121,"title":["Renal toxicities associated with pembrolizumab"],"prefix":"10.1093","volume":"12","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[{"name":"Department of Nephrology, Peupliers Private Hospital, Ramsay G\u00e9n\u00e9rale de Sant\u00e9, Paris, France"},{"name":"UPEC (Universit\u00e9 Paris Est Cr\u00e9teil), INSERM U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB), Equipe, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Mathian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pitie-Salpetriere Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-4531","authenticated-orcid":false,"given":"C\u00e9cile","family":"Picard","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pitie-Salpetriere Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mateus","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Routier","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dermatology Unit, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Varga","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gastrointestinal Cancer Group, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gynecology Unit, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Michels","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gynecology Unit, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Bicetre University Hospital, Le Kremlin Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pitie-Salpetriere Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[{"name":"Drug Development Department (DITEP), Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Kaaki","sequence":"additional","affiliation":[{"name":"Departement of Pathology, Electron Microscopy Unit, CHU Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Quellard","sequence":"additional","affiliation":[{"name":"Departement of Pathology, Electron Microscopy Unit, CHU Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Goujon","sequence":"additional","affiliation":[{"name":"Departement of Pathology, Electron Microscopy Unit, CHU Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brocheriou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pitie-Salpetriere Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B1","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B2","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (ca184\u2013043): a multicentre, randomised, double-blind, Phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10637-015-0243-5","article-title":"Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in japanese patients with non-small-cell lung cancer","volume":"33","author":"Horinouchi","year":"2015","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, Phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B7","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","article-title":"A Phase I dose escalation trial of tremelimumab (cp-675, 206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B8","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"Mcdermott","year":"2015","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00262-011-1193-1","article-title":"Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer","volume":"61","author":"Mcneel","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B11","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2147\/DDDT.S146286","article-title":"Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B12","first-page":"936","article-title":"Renal effects of immune checkpoint inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1801663","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Jhaveri","year":"2018","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12032-010-9606-0","article-title":"Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy","volume":"28","author":"Harmankaya","year":"2011","journal-title":"Med Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B17","first-page":"4A","article-title":"Immune-related adverse events (irAEs) following CTLA-4 and PD-1\/PD-L1 blockade in advanced melanoma: a comprehensive rapid autopsy study","volume":"29 (Suppl 2)","author":"Bavi","year":"2016","journal-title":"Mod Pathol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B19","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.kint.2016.05.024","article-title":"Checkmate: kidney injury associated with targeted cancer immunotherapy","volume":"90","author":"Perazella","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/PAP.0000000000000122","article-title":"Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies","volume":"23","author":"Troxell","year":"2016","journal-title":". Adv Anat Pathol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab-associated minimal change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"A case of IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","article-title":"Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma","volume":"16","author":"Bickel","year":"2016","journal-title":"BMC Cancer"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.1986.209","article-title":"Neoplasia and glomerular injury","volume":"30","author":"Alpers","year":"1986","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0002-9343(86)90049-5","article-title":"Glomerular lesions in lymphomas and leukemias","volume":"80","author":"Dabbs","year":"1986","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B34","first-page":"vi52","article-title":"Secondary minimal change disease","volume":"18 (Suppl 6)","author":"Glassock","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000013365","article-title":"Recovery of minimal change nephrotic syndrome and acute renal failure in a patient with renal cell carcinoma","volume":"18","author":"Auguet","year":"1998","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000168592","article-title":"Minimal change glomerulopathy and carcinoma. Report of two cases and review of the literature","volume":"13","author":"Martinez-Vea","year":"1993","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B38","first-page":"37","article-title":"A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome","volume":"23","author":"Lagrue","year":"1975","journal-title":"Biomedicine"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B39","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis","volume":"5","author":"McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B40","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","article-title":"Induction of B7-1in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B41","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1- positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2015030266","article-title":"B7-1 is not induced in podocytes of human and experimental diabetic nephropathy","volume":"27","author":"Gagliardini","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B44","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B45","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B46","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1200\/JCO.2012.47.5095","article-title":"Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab","volume":"13","author":"Minor","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B47","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kes034","article-title":"Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis","volume":"51","author":"Wilde","year":"2012","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019020706495159200_sfy100-B48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.clim.2008.03.506","article-title":"Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis","volume":"128","author":"Slot","year":"2008","journal-title":"Clin Immunol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/12\/1\/81\/27721453\/sfy100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T07:21:52Z","timestamp":1549524112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/12\/1\/81\/5168430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,11,9]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfy100","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,11,9]]}}}